Hypoxia-regulated secretion of IL-12 enhances antitumor activity and safety of CD19 CAR-T cells in the treatment of DLBCL

CD19-targeted chimeric antigen receptor-modified T (CD19 CAR-T) cell therapy has been demonstrated as one of the most promising therapeutic strategies for treating B cell malignancies. However, it has shown limited treatment efficacy for diffuse large B cell lymphoma (DLBCL). This is, in part, due t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Wenping, Miao, Jinxin, Cheng, Zhenguo, Wang, Zhimin, Wang, Jianyao, Guo, Haoran, Wang, Pengju, Lu, Shuangshuang, Si, Lingling, Zhang, Zhongxian, Dunmall, Louisa Chard, Liu, Yanyan, Lemoine, Nicholas R., Wang, Yaohe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471514/
https://www.ncbi.nlm.nih.gov/pubmed/37663131
http://dx.doi.org/10.1016/j.omto.2023.08.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471514/
https://www.ncbi.nlm.nih.gov/pubmed/37663131
http://dx.doi.org/10.1016/j.omto.2023.08.009

Ejemplares similares